Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations

Shanni Vaismann; Nili Stein; Liat Dizengoff; Amir Warwar; Shoshan Perek; Ibraheem Zoabi; Walid Saliba; Meir Preis

doi:10.1055/a-2347-4338

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2025; 125(01): 082-084
DOI: 10.1055/a-2347-4338

Letter to the Editor

Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations

Authors

Shanni Vaismann

¹Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

²Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel
Nili Stein

³Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel
Liat Dizengoff

²Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel
Amir Warwar

¹Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

²Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel
Shoshan Perek

²Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel
Ibraheem Zoabi

²Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel
Walid Saliba

¹Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

³Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel
Meir Preis

¹Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

²Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel

Abstract

Full Text

References

References
1 Shpilberg O, Peretz H, Zivelin A. et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85 (02) 429-432
2 Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009; 7 (Suppl. 01) 84-87
3 Gailani D, Broze Jr GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253 (5022): 909-912
4 Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99 (10) 2323-2327
5 Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12 (05) 490-493
6 Preis M, Hirsch J, Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129 (09) 1210-1215
7 De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J 2023; 44 (04) 280-292
8 Greco A, Laudani C, Spagnolo M. et al. Pharmacology and clinical development of factor XI inhibitors. Circulation 2023; 147 (11) 897-913
9 Galli M, Laborante R, Ortega-Paz L. et al. Factor XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost 2023; 123 (06) 576-584